AstraZeneca, Eledon and Alpine spell out kidney program successes: ASN roundup
06 Nov 2023
Phase 2Clinical Result
Over the past few days, Big Pharma and biotech companies alike presented results at the American Society of Nephrology’s annual kidney week. Endpoints News sifted through the data to highlight several key readouts, including those that triggered notable stock reactions or pushed forward a new mechanism.
AstraZeneca’s ETA antagonist succeeds in mid-stage CKD trial
On Friday, AstraZeneca unveiled positive data from the Phase IIb ZENITH-CKD study of its investigational ETA receptor antagonist, zibotentan, in combination with SGLT2 inhibitor Farxiga in chronic kidney disease. The pharma major plans to advance the combination to a Phase III trial with 1,500 people, set to start in the first quarter of 2024.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.